Sandu Pharmaceuticals Limited has filed its quarterly compliance statement with the Bombay Stock Exchange (BSE) confirming no deviation in the utilization of funds raised through preferential issue for the quarter ended December 31, 2025. The statement, submitted on February 6, 2026, covers three separate tranches of fund raising conducted between 2021 and 2022.

Fund Utilization Across Three Tranches

The company reported complete adherence to original fund utilization objectives across all three tranches of preferential issue. The comprehensive statement demonstrates systematic fund deployment for intended business purposes.

Original Fund Utilization Objectives

The proceeds from all three tranches were designated for specific business enhancement activities. The company allocated funds toward revamping existing capital machinery, developing marketing infrastructure, and civil work required for major plant and machinery. Additional objectives included:

• Purchase of new and additional plant and machinery
• Working capital requirements
• Investment in new technologies
• General business enhancement purposes

Regulatory Compliance and Oversight

The statement was prepared pursuant to Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 and SEBI Circular CIR/CFD/CMD1/162/2019 dated December 24, 2019. The Audit Committee reviewed the statement and noted approval of the fund utilization pattern across all tranches.

Outstanding Fund Balance

For the third tranche, the company maintains unutilized funds in an escrow account as of December 31, 2025. A fixed deposit has been created in the name of the company with Bank of Baroda to facilitate fund utilization as and when required for approved objectives.

The statement was signed by Pratika Mhambray, Company Secretary & Compliance Officer, and Umesh Sandu, Managing Director (DIN: 01132141), confirming the accuracy of the reported fund utilization status.

Sandu Pharmaceuticals Limited has announced its unaudited standalone financial results for the third quarter of FY26 ended 31st December 2025, demonstrating strong financial performance with significant profit growth. The Ayurvedic pharmaceutical company's results were approved by the board of directors during their meeting held on 6th February 2026.

Financial Performance Highlights

The company delivered impressive results for Q3FY26, with net profit reaching ₹97.51 lakhs compared to ₹55.55 lakhs in the corresponding quarter of the previous year. This represents substantial growth in profitability for the quarter. Revenue from operations stood at ₹1876.09 lakhs for Q3FY26, compared to ₹1837.29 lakhs in Q3FY25.

Nine-Month Performance

For the nine-month period ended 31st December 2025, Sandu Pharmaceuticals reported revenue from operations of ₹5308.10 lakhs and net profit of ₹172.27 lakhs. The company maintained consistent performance across the nine-month period with total income reaching ₹5316.04 lakhs.

Earnings Per Share and Capital Structure

The company reported basic and diluted earnings per share of ₹1.01 for Q3FY26, compared to ₹0.57 in Q3FY25. For the nine-month period, basic EPS stood at ₹1.78 compared to ₹1.27 in the previous year. The paid-up equity capital remained stable at ₹966.10 lakhs with a face value of ₹10 per share.

Comprehensive Income and Other Highlights

Total comprehensive income for Q3FY26 reached ₹114.47 lakhs, including other comprehensive income from fair value changes of investments amounting to ₹19.70 lakhs. For the nine-month period, total comprehensive income stood at ₹213.43 lakhs.

Corporate Governance and Compliance

The financial results were reviewed and recommended by the audit committee before being approved by the board of directors. The results have been prepared in accordance with Indian Accounting Standards (Ind AS) and SEBI regulations. The company operates primarily in the Ayurvedic pharmaceutical medicines segment and maintains ISO 9001:2015 certification along with Good Manufacturing Practices (GMP) certification.